In this video, Camilla W. Kilbane, MD, discusses how to approach monitoring patients after they initiate treatment for tardive dyskinesia.

Our next question comes from the line of Yatin Suneja with Guggenheim. Your line is now open.

Germany: A recent phase 3 randomized, placebo-controlled trial published in Nature Medicine in September 2025 reports that a standardized full-spectrum cannabis extract (VER-01) significantly reduces ...

MedStar Health launched its premier concierge medicine practice, called Signature by MedStar Health, in September and is ...

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

For almost 30 years, students at Iron Mountain Schools have benefited from the academic booster club’s dedication to providing equipment and support for programs. In conjunction with this milestone, ...

At this time, I would like to welcome everyone to Harmony Biosciences' Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's ...

Insmed Incorporated (NASDAQ:INSM) Q4 2025 Earnings Call Transcript February 19, 2026 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.54 EPS, expectations were $-1.07. Operator ...

Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's. Find out why AVXL stock is a Sell.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.38 EPS, expectations were $-0.

The Pulse team looks at the changes to the GP contract for the next financial year and what it will all mean for practices.

Neuroscience reveals why some people perform brilliantly under pressure but unravel when life is calm — and how a threat-adapted nervous system can learn to tolerate safety.